ARCA biopharma, Inc.
(NASDAQ : ABIO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.08%132.190.0%$1230.60m
OCGNOcugen, Inc. -2.56%8.740.0%$941.39m
NVAXNovavax, Inc. 10.59%174.8492.9%$613.91m
REGNRegeneron Pharmaceuticals, Inc. 2.71%461.572.7%$556.12m
AMGNAmgen, Inc. 2.62%227.731.3%$540.12m
GILDGilead Sciences, Inc. 2.20%64.621.0%$516.91m
ILMNIllumina, Inc. -0.19%398.853.5%$484.87m
VRTXVertex Pharmaceuticals, Inc. 2.02%211.981.9%$458.30m
ALXNAlexion Pharmaceuticals, Inc. 1.11%150.102.0%$339.49m
BIIBBiogen, Inc. 2.71%270.711.7%$305.38m
CRSPCRISPR Therapeutics AG -0.73%114.650.6%$304.78m
BNGOBioNano Genomics, Inc. 3.62%7.150.0%$275.81m
EXASEXACT Sciences Corp. 0.51%121.6418.4%$251.13m
SGENSeagen Inc. 2.68%149.355.8%$225.25m
PACBPacific Biosciences of California, Inc. 1.70%29.277.2%$176.23m

Company Profile

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.